English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Prospective audit and feedback (PAF) is a cornerstone of antibiotic stewardship (AS). PAF reduces inappropriate antibiotic use, decreases resistance, and improves outcomes. A major drawback of PAF is the significant time commitment required to determine which patients are on inappropriate antibiotics. The aim of this study was to describe features of a cohort of patients targeted for PAF and to identify factors associated with PAF intervention. Methods Retrospective cohort of all inpatients at UCSF Medical Center, who received a broad-spectrum antibiotic targeted by the AS program for PAF. Data were extracted from the electronic medical record. The outcome of interest was whether the AS team documented a recommendation (“rec”) on any given day. Univariate analyses were performed using chi-squared tests for categorical data and t-tests for continuous data to compare variables Results Between December 15, 2015 and August 1, 2017, 9651 adult patients received at least one “targeted” antibiotic with a total of 62,095 days of therapy comprising 18,275 antibiotic courses (mean 1.9 courses/patient × 3.4 days) with 684 AS interventions made. Time to AS intervention was 4.6 days (±4.3). Table 1 shows factors associated with PAF intervention. Conclusion Factors associated with PAF intervention can help to prioritize patients for review by the AS team. These factors will be used to develop predictive models to improve the efficiency and effectiveness of PAF. Table 1. Overall Rec No Rec P value By course n = 18,275 n = 684 n = 17,591 Female 7,922(43.4%) 288(42.1%) 7,634(43.4%) NS Age (years) 56.8 57.5 56.8 NS Service Medical 9,087(49.7%) 339(49.6%) 8,748(49.7%) Surgical 4,694(25.7%) 157(23.0%) 4,537(25.8%) Transplant 4,494(24.6%) 188(27.5%) 4,306(24.5%) NS # of Abx 1.8 2.3 1.7 <0.05 + BCx 1,373(7.5%) 130(19.0%) 1,243(7.0%) <0.05 ICU 4,504(24.7%) 285(41.7%) 4,219(24.0%) <0.05 Prior ID consult 2,491(13.6%) 45(6.7%) 2,446(13.9%) <0.05 By day n = 62,095 n = 684 n = 61,411 WBC Count 10.1 10.2 10.1 NS Tmax 37.3 37.4 37.3 0.07 Abx Meropenem 5,611(9.0%) 152(22.2%) 5,459(8.9%) <0.05 Piperacillin–tazobactam 18,334(29.5%) 303(44.3%) 18,031(29.4%) <0.05 Cefepime 7,184(11.6%) 76(11.1%) 7,108(11.6%) NS Vancomycin 27,106(43.7%) 414(60.5%) 26,692(43.5%) <0.05 Disclosures S. B. Doernberg, Genentech: Consultant, Consulting fee. Actelion: Consultant, Consulting fee.

1818. Characteristics of a Cohort of Patients on Broad-Spectrum Antibiotics Targeted for Prospective Audit and Feedback